Gene therapy proves successful in treating hereditary deafness
- PMID: 38796197
- DOI: 10.1016/S0140-6736(24)00496-3
Gene therapy proves successful in treating hereditary deafness
Conflict of interest statement
ER is a former employee of University Medical Center Göttingen (Göttingen, Germany) and co-inventor on a patent for dual-AAV vectors to restore hearing (WO2021168362). The University Medical Center Göttingen has licensed the rights to these parts of the patent exclusively to Akouos (Boston, MA, USA). ER is a consultant for Akouos. IT is a principal investigator at Fondazione Telethon Institute of Genetics and Medicine and co-inventor on patents for dual-AAV vectors gene therapy approaches (WO2014/170480A1, WO2016/139321A1, and WO2020079034A2). Fondazione Telethon has licensed the rights to these patents. ER receives funding from the Deutsche Forschungsgemeinschaft via the Heisenberg Program (416097726). IT is supported by grants from the Fondazione Telethon (TMITMFU22TT), the Italian Ministry of Research (EJP RD programme, DEC 790; and PRIN_2022_PNRR, P2022CAX4C), and the Italian Ministry of Health (PNRR-MR1-2022-12376747).
Comment on
-
AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial.Lancet. 2024 May 25;403(10441):2317-2325. doi: 10.1016/S0140-6736(23)02874-X. Epub 2024 Jan 24. Lancet. 2024. PMID: 38280389 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
